Search Full Text
Now showing items 1-3 of 3
The Molecular Determinants of Tumor Cell Sensitivity and Resistance to Antibody-Dependent Cellular Cytotoxicity (ADCC)
(Georgetown University, 2013)
Monoclonal antibodies represent the vanguard of targeted therapy due to their specificity and versatility. Aside from disrupting tumor cell survival and proliferation through cell surface receptor interactions, antibodies ...
CIRCUMVENTING ANTIGEN LOSS TO POTENTIATE CANCER IMMUNOTHERAPY
(Georgetown University, 2015)
Cancer cells become resistant to monoclonal antibody (mAb) therapy when they lose the cell surface antigens that mAbs target. To circumvent immune escape and maximize the efficacy of mAb therapy, new approaches to mitigate ...
T Cell Based Immunotherapy Targeting Fibroblast Growth Factor Receptor 4 as a Therapeutic against Rhabdomyosarcoma
(Georgetown University, 2019)
Rhabdomyosarcoma (RMS), the most common soft tissue sarcoma of childhood, has a low mutational burden with few actionable somatic targets. Fibroblast growth factor receptor 4 (FGFR4) is a candidate therapeutic target in ...